Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Begoña Ares"'
Publikováno v:
Clinical Parkinsonism & Related Disorders, Vol 6, Iss , Pp 100129- (2022)
Introduction: Parkinson’s disease (PD) patients usually start treatment with apomorphine infusion (APO) in later stages of advanced PD (aPD). This timing limits the evaluation of its motor efficacy and other potential clinical benefits throughout t
Externí odkaz:
https://doaj.org/article/41e5c739986849a386818c7173df0178
Publikováno v:
Revista Mexicana de Neurociencia, Vol 22, Iss 4 (2021)
Identifying the advanced stage in Parkinson’s disease (PD) is crucial for shifting from conventional to device-aided therapies. The criteria to define the onset of advanced PD have been based on lengthy and disabling daily off-times, troublesome dy
Externí odkaz:
https://doaj.org/article/bbf4631430424bc998d08bfc4ee99e9b
Autor:
Gustavo Fernández-Pajarín, Ángel Sesar, José Luis Relova, Begoña Ares, Isabel Jiménez, Miguel Gelabert-González, Eduardo Arán, Alfonso Castro
Publikováno v:
Diagnostics, Vol 12, Iss 4, p 1001 (2022)
Background: The relationship between axial symptoms in Parkinson’s disease (PD) and subthalamic deep brain stimulation (STN-DBS) is still unclear. Purpose: We searched for particular clinical characteristics before STN-DBS linked to on-state axial
Externí odkaz:
https://doaj.org/article/5d7a234da12442daa2497927ff384138
Autor:
José Luis Relova, Ángel Sesar, A. Castro, Miguel Gelabert, Eduardo Arán-Echabe, Gustavo Fernández-Pajarín, Isabel Jiménez-Martín, Begoña Ares
Publikováno v:
Movement Disorders Clinical Practice
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname
Background: Background Studies comparing the clinical efficacy of apomorphine infusion (APO) with subsequent subthalamic deep brain stimulation (STN-DBS) in advanced Parkinson’s disease (aPD) are currently lacking. Retrospective data have shown tha
Publikováno v:
Clinical Parkinsonism & Related Disorders
Clinical Parkinsonism & Related Disorders, Vol 6, Iss, Pp 100129-(2022)
Clinical Parkinsonism & Related Disorders, Vol 6, Iss, Pp 100129-(2022)
Highlights • A prospective analysis of APO treatment of 22 PD patients in the initial stages of advanced PD. • Motor and non-motor symptoms, cognitive function and quality of life were assessed over 6 months. • APO resulted in significant impro
Publikováno v:
Revista Mexicana de Neurociencia, Vol 22, Iss 4 (2021)
Identifying the advanced stage in Parkinson’s disease (PD) is crucial for shifting from conventional to device-aided therapies. The criteria to define the onset of advanced PD have been based on lengthy and disabling daily off-times, troublesome dy
Autor:
José Luis Relova, Begoña Ares, Ángel Sesar, Eduardo Arán, Miguel Gelabert-González, A. Castro, Gustavo Fernández-Pajarín, María-Teresa Rivas
Publikováno v:
Journal of Neurology. 266:659-666
Deep brain stimulation (DBS) is an effective therapy for patients with advanced Parkinson’s disease (PD). However, sometimes, it is not sufficient to adequately control motor symptoms. We describe our experience with continuous subcutaneous apomorp
Publikováno v:
Neurología.
Resumen Introduccion Las mutaciones en el gen LRRK2 se han relacionado tradicionalmente con un fenotipo benigno de la enfermedad de Parkinson (EP). En la fase avanzada, se ha descrito una respuesta favorable a la estimulacion cerebral profunda (ECP).
Autor:
Ángel Sesar, José Luis Relova, A. Castro, Miguel Gelabert-González, Begoña Ares, Gustavo Fernández-Pajarín, E Arán
Publikováno v:
Acta Neurochirurgica. 159:1713-1719
Over the years, most of the deep brain stimulation (DBS) complications described have been mainly related to the surgery itself or the stimulation. Only a few authors have dealt with chronic complications or complications due to implanted material. W
Autor:
José Luis Relova, Miguel Gelabert-González, Ángel Sesar, Gustavo Fernández-Pajarín, A. Castro, Patricia Blanco-Arias, Begoña Ares, I. Jiménez-Martín
Publikováno v:
Acta Neurochirurgica. 158:2023-2028
Myoclonus-dystonia syndrome (MDS) is an autosomal dominant movement disorder caused by mutations in the SGCE gene. MDS is characterized by mild dystonia and myoclonic jerks, and a constellation of psychiatric manifestations. Deep brain stimulation (D